Language:

Effect of different antidiabetic medications on atherosclerotic cardiovascular disease (ASCVD) risk score among patients with type-2 diabetes mellitus: A multicenter non-interventional observational study

PloS one, 2022-06, Vol.17 (6), p.e0270143-e0270143 [Peer Reviewed Journal]

COPYRIGHT 2022 Public Library of Science ;2022 Gillani et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2022 Gillani et al 2022 Gillani et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0270143 ;PMID: 35763504

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Effect of different antidiabetic medications on atherosclerotic cardiovascular disease (ASCVD) risk score among patients with type-2 diabetes mellitus: A multicenter non-interventional observational study
Author: Gillani, Syed Wasif ; Syed Sulaiman, Syed Azhar ; Menon, Vineetha ; Rahamathullah, Nazeerullah ; Elshafie, Riham Mohamed ; Rathore, Hassaan Anwer
Serra, Raffaele
Subjects: Antidiabetics ; Arteriosclerosis ; Atherosclerosis ; Biology and Life Sciences ; Blood pressure ; Body mass index ; Cardiovascular disease ; Cardiovascular diseases ; Care and treatment ; Clinical outcomes ; Comorbidity ; Complications and side effects ; Diabetes ; Diabetes mellitus ; Diabetes mellitus (non-insulin dependent) ; Diabetes therapy ; Emergency medical services ; Evaluation ; FDA approval ; Glucagon ; Glucose ; Health risks ; Hemoglobin ; Heterogeneity ; Hypoglycemia ; Insulin ; Lipids ; Low density lipoprotein ; Mathematical analysis ; Medicine and Health Sciences ; Metformin ; Mortality ; Observational studies ; Patient outcomes ; Patients ; Peptidase ; Peptidases ; Peptides ; Plasma ; Prescription drugs ; Renal function ; Risk assessment ; Risk management ; Risk reduction ; Social factors ; Sulfonylurea ; Triglycerides
Is Part Of: PloS one, 2022-06, Vol.17 (6), p.e0270143-e0270143
Description: Objective The aim of this study was to compare the clinical outcomes associated with different combinations of oral diabetic drugs among patients with type 2 diabetes mellitus. Method A prospective multicenter longitudinal, noninterventional observation study design was applied. At baseline (0 month), clinical parameters including glucose profile, renal function, lipid profile and risk assessment for cardiovascular risks were calculated. Mean Weighted difference (MWD) with heterogeneity and effect z was calculated to determine the risk reduction at the end of the study. Results A total of 1,657 were enrolled to different cohorts with response rate of 75.5%. The distribution of patients was based on prescribed drug. A total of 513 (30.9%) in G1 (metformin alone), 217 (13.09%) in G2 (metformin with Glimepiride), 231 (12.85%) in G3 (Metformin with Gliclazide), 384 (23.17%) in G4 (metformin with Sitagliptin) and 312 (18.89%) in G5 (Metformin with Saxagliptin). There was no significant different in all clinical and social variables at baseline. The Intergroup analysis showed significant differences with all the primary outcome variables except BMI (p = 0.217) and eGFR (p = 0.782) among patients using sulphonylurea (SU) combination (G2 & G3). Findings also showed significant high frequency of emergency visit and hospitalization in G1 (78.16% & 30.8%) as compared to SU (70.1% & 28.3%, p = 0.001) and DPP-4 (56.6% & 20.4%, p = 0.001). The overall reported effect was z = 2.58, p = 0.001 for ASCVD risk reduction assessment. Conclusion The study concluded that significant effect of Dipeptidyl peptidase-4 inhibitor on reduction of hospitalization, lipid profile and also ASCVD risk score of type-II diabetes mellitus patients regardless of clinical comorbidities. Also, sulfonylurea combinations have showed significant reduction in LDL and triglycerides values.
Publisher: San Francisco: Public Library of Science
Language: English
Identifier: ISSN: 1932-6203
EISSN: 1932-6203
DOI: 10.1371/journal.pone.0270143
PMID: 35763504
Source: GFMER Free Medical Journals
PubMed Central
Public Library of Science (PLoS)
ProQuest Central
DOAJ Directory of Open Access Journals

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Effect of different antidiabetic medications on atherosclerotic cardiovascular disease (ASCVD) risk score among patients with type-2 diabetes mellitus: A multicenter non-interventional observational study

Searching Remote Databases, Please Wait